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Tuesday, March 2, 2021 
 
 
During this COVID-19 pandemic and other future events, the CDM has been 
and will continue to be a source of reliable information, education and models 
for mitigation, preparedness, response, and recovery.  We hope this 
informational document has helped provide you filtered and actionable 
information.  As the pace of new information and changes occur, we will 
evaluate the current once per week to determine if this information should be 
provided on a more frequent basis.   
 
 
                                                                                                                        
David Markenson, M.D., M.B.A. 
Director 









Worldwide 114,499,553 2,540,340 64,690,916 Not Available 
United States 28,664,604 514,660 Not Available 351,801,124 
New Jersey 792,496 23,273 Not Available 10,660,578 
New York 1,650,303 47,719 Not Available 38,281,073 
Connecticut 282,626 7,651 Not Available 6,403,426 
 
Information as of 3/2/21 at 1000 EST. Source: https://coronavirus.jhu.edu/map.html  
 
 







Center for Disaster Medicine Updates 
 
● Delivered All Hazards Disaster Response course to members of different public safety 
agencies from New York and Connecticut  
● Presented lecture regarding disaster medicine, emergency management and COVID-19 to 
graduating class of NYU Rory Meyers College of Nursing students 
● Coordinating and overseeing COVID-19 screenings at NYMC campus 
● Continue to partner with local agencies such as Westchester Department of Emergency 
Services to ensure ongoing collaboration with all public safety agencies. 
● Coordinating volunteers to support local public health response to COVID-19. 
● Conducting research and analysis of current events and COVID-19 response to identify 
strengths and areas for improvement in other regions. 
● Updating and developing new programs to provide enhanced education on public health 
emergencies including pandemics. 
● Exploring course development opportunities in infection prevention and control for frontline 
responders in the hospital and in the field. 
● Serving as a source of information for COVID-19 related concerns or questions regarding 
public health, emergency medical service (EMS), public safety and healthcare response.  
● Local networking and pandemic response analysis for New York’s tri-state area, using first-
person experiences to highlight current trends. 
 
To view the Center for Disaster Medicine's newest webinar, please click here - The 
COVID-19 Vaccine: What to Tell Your Patients 
 
The White House 
 
The official website of the White House  delivers bold action and immediate relief for American 
families as the country grapples with converging crises. This  includes actions to control the 
COVID-19 pandemic, provide economic relief, tackle climate change, and advance racial equity 
and civil rights, as well as immediate actions to reform our immigration system and restore 





Health and Human Services (HHS) 
 
For the latest COVID-19 information from HHS 
https://www.hhs.gov/about/news/coronavirus/index.html 
 
National Institutes of Health (NIH) 
 
  
A research team funded by the National Institutes of Health has launched a study to assess 
performance and usability of a smartphone app paired with the Quidel QuickVue At-Home 
COVID-19 Test, which just received an Emergency Use Authorization  (EUA) from the U.S. Food 
and Drug Administration for use with a prescription. The home test was supported by NIH 
through the Rapid Acceleration of Diagnostics (RADx) initiative, which has spurred the 
development and commercial availability of millions of COVID-19 tests over the past year. 
https://www.nih.gov/news-events/news-releases/nih-evaluate-covid-19-home-testing-system  
 
The U.S. Food and Drug Administration issued an Emergency Use Authorization (EUA) to the 
Janssen Pharmaceuticals Companies of Johnson & Johnson for its single-shot COVID-19 
vaccine, called Ad.26.COV2S or JNJ-78436725. The Janssen vaccine is a recombinant vector 
vaccine that uses a human adenovirus to express the spike protein found on the surface of the 




 People who have had evidence of a prior infection with SARS-CoV-2, the virus that causes 
COVID-19, appear to be well protected against being reinfected with the virus, at least for a few 
months, according to a newly published study from the National Cancer Institute (NCI). This 
finding may explain why reinfection appears to be relatively rare, and it could have important 
public health implications, including decisions about returning to physical workplaces, school 









United States Food and Drug Administration (FDA) 
 
As of February 26, 2021, 332 tests and sample collection devices are authorized by the 
FDA under emergency use authorizations (EUAs). These include 248 molecular tests and 
sample collection devices, 70 antibody tests, and 14 antigen tests. There are 37 
molecular authorizations that can be used with home-collected samples. There is one 
molecular prescription at-home test, one antigen prescription at-home test, and one over-




On February 27, 2021, the U.S. Food and Drug Administration issued an emergency use 
authorization (EUA) for the third vaccine for the prevention of coronavirus disease 2019 
(COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 
The EUA allows the Janssen COVID-19 Vaccine to be distributed in the U.S for use in 
individuals 18 years of age and older. The EUA for the Janssen COVID-19 Vaccine was 









Centers for Disease Control and Prevention (CDC) 
 
CDC is closely monitoring mutations in the virus genome that alter the characteristics and 
cause the virus to act differently in ways that are significant to public health (e.g., causes 
more severe disease, spreads more easily between humans, requires different 
treatments, changes the effectiveness of current vaccines). It’s important to understand 
that genetic mutations are expected, and some variants can spread and become 
predominant while others subside. 
https://www.cdc.gov/coronavirus/2019-ncov/transmission/variant-cases.html  
 
CDC is responding to the COVID-19 pandemic by learning more about how the disease 
spreads and affects people and communities. CDC’s Morbidity and Mortality Weekly 
Report publishes the results of COVID-19 outbreak investigations. CDC’s scientific journal 
Emerging Infectious Diseases has published dozens of studies by researchers studying 
COVID-19 since the pandemic began. 
https://www.cdc.gov/coronavirus/2019-ncov/more/science-and-research.html  
 
CDC provides update on COVID-19 cases caused by variants in the United States. 
https://www.cdc.gov/coronavirus/2019-ncov/transmission/variant-cases.html  
 
For daily updates of cases in United States 
https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/cases-in-us.html 
 
For the latest CDC information 
https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/index.html 
 
Center for Medicare and Medicaid Services (CMS)  
In accordance with the Executive Order President Biden signed on January 21, 2021, the 
Centers for Medicare & Medicaid Services (CMS), together with the Department of Labor 
and the Department of the Treasury, (collectively, the Departments) issued new guidance 
today removing barriers to COVID-19 diagnostic testing and vaccinations and 










In this section, vaccine-related information from various sources will be collected, 
reviewed, and tabulated here.  As of March 2, 2021, the FDA has granted Emergency 
Use Authorization (EUA) to Pfizer BioNTech, Moderna and Janssen/Johnson & Johnson. 
Now with three vaccines with EUA, the goal is to vaccinate a larger number of persons in 
the coming months throughout the United States. As additional vaccines are granted 
EUA, information for those vaccines will also be included. 
FDA grants Emergency Use Authorization (EUA) to Janssen COVID-19 Vaccine- On 
February 27, 2021, the U.S. Food and Drug Administration issued an emergency use 
authorization (EUA) for the third vaccine for the prevention of coronavirus disease 2019 
(COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 
The EUA allows the Janssen COVID-19 Vaccine to be distributed in the U.S. for use in 




On December 18, 2020, the U.S. Food and Drug Administration issued an emergency use 
authorization (EUA) for the second vaccine for the prevention of coronavirus disease 
2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2). The emergency use authorization allows the Moderna COVID-19 Vaccine to be 




On December 11, 2020, the U.S. Food and Drug Administration issued the first 
emergency use authorization (EUA) for a vaccine for the prevention of coronavirus 
disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) in individuals 16 years of age and older. The emergency use authorization 




CDC provides overall U.S. COVID-19 Vaccine, deliveries and administration, maps, 
charts, and data updated daily by 8 p.m. This section represents all vaccine partners 
including jurisdictional partner clinics, retail pharmacies, long-term care facilities, Federal 
Emergency Management Agency and Health Resources and Services Administration 
partner sites, and federal entity facilities. 
https://covid.cdc.gov/covid-data-tracker/#vaccinations  
 
Media Statement from CDC Director Rochelle P. Walensky, M.D., M.P.H., on Signing the 
Advisory Committee on Immunization Practices’ Recommendation to Use Janssen’s 
COVID-19 Vaccine in People 18 and Older 
https://www.cdc.gov/media/releases/2021/s0228-JJ-vaccine.html  
 
CDC created this section regarding the Moderna vaccine to provide updated relevant 
information including side effects and safety data, clinical trials demographic statistics, 
and information on how the vaccine works. 
https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/Moderna.html   
 
CDC created this section regarding the Pfizer BioNTech vaccine to provide updated 
relevant information including side effects and safety data, clinical trials demographic 




HHS created this section to provide the latest information about COVID-19 vaccines. 
https://www.hhs.gov/coronavirus/covid-19-vaccines/index.html  
 
New York State Governor Andrew M. Cuomo today announced that the New York State 
Clinical Advisory Task Force unanimously recommended use of Janssen 
Pharmaceuticals/Johnson & Johnson's COVID-19 vaccine in New York State, following 
the FDA's advisory committee's recommendation for emergency use authorization. New 
York expects to receive approximately 164,800 doses of the Johnson & Johnson vaccine 
this week, pending final FDA authorization. The added doses will supplement New York 
State's expected Week 12 supply of 422,780 first doses and 290,500 second doses from 
Pfizer and Moderna, for a total of approximately 878,080 doses. This will be New York 




The COVID-19 vaccines are here. Supply from the Federal Government is extremely 
limited. Additional New Yorkers will become eligible as the vaccine supply increases. 
While the vaccination process is underway, every New Yorker should wear a mask, social 
distance and avoid small and large gatherings. Governor Cuomo revised the eligibility list 
of persons to include any New Yorker of any age with certain comorbidities and 
underlying conditions effective February 15, 2021.  
https://covid19vaccine.health.ny.gov/phased-distribution-vaccine#phase-1a---phase-1b  
 
The new NYS DOH COVID-19 Vaccine Tracker Dashboard will update New Yorkers on 
the distribution of the vaccine including the number of doses received by the state, a 
breakdown of first or second doses, and the number of persons vaccinated with the first 
and second doses in each region. 
https://covid19vaccine.health.ny.gov/covid-19-vaccine-tracker  
 
NYS DOH releases instructions for New York State-operated vaccination sites 
https://covid19vaccine.health.ny.gov/  
 
For NYC DOHMH updated guidance regarding COVID-19 vaccine 
https://www1.nyc.gov/site/doh/covid/covid-19-vaccines.page  
 
The Vaccine Finder is a one-stop site for New Yorkers to find their nearest COVID-19 
vaccination location. The Vaccine Finder can also provide New Yorkers with information 
to schedule vaccination appointments. 
https://vaccinefinder.nyc.gov/  
 
Educational Institution Information 
• Higher Education 
o A years-long push to lessen the incentive for for-profit institutions to 
recruit veterans as students took a major step toward becoming law with 
the House’s passage of a $1.9 trillion coronavirus relief package 
Saturday morning. Included in the package, which would also send 
another $40 billion in aid to the nation’s colleges and universities during 
the pandemic, was a provision tightening the controversial "90-10" rule. 
The for-profit industry, however, is expected to try to kill the change when 
the Senate takes up the relief package this week, warning that the 
change pushed by Democrats would inadvertently lead to for-profits 
accepting fewer veterans and members of the military. The proposal did 
survive one hurdle Monday night when the Senate's parliamentarian ruled 
that it could stay in the bill, according to groups on both sides of the 
debate. For-profit industry lobbyists had hoped the parliamentarian would 
rule that the measure goes beyond what is allowable in the funding bill, 
as she did in killing the Democratic proposal to raise the federal minimum 
wage. https://www.insidehighered.com/news/2021/03/02/provision-covid-
19-relief-bill-would-ease-incentives-profits-target-veterans  
o More than half of students worldwide, and three-quarters in the U.S., said 
their mental health has suffered during the COVID-19 pandemic, 
according to a new survey of nearly 17,000 undergraduate students 
across 21 countries commissioned by the nonprofit arm of Chegg, 
a controversial textbook rental and educational technology company. 
Chegg.org commissioned the polling company Yonder to interview 
16,839 undergraduates across the 21 countries last fall, with sample 
sizes in the various countries ranging from 500 to about 1,000. Seventy-
five percent of American students surveyed said their mental health had 
suffered due to the pandemic, second only to Brazil (76 percent) and 
similar to the percentage of Canadian students who said the same 
(73 percent). Worldwide, across the nearly two dozen countries where 
students were surveyed, 56 percent of students said their mental health 





o As state leaders regroup to plan a path forward, district administrators are 
"at the mercy" of their decisions, said education policy expert Cara 
Jackson, an associate partner at Bellwether Education Partners. Aside 
from the remote option, states can shorten assessments, offer multiple 
testing windows and extend testing until fall 2021, according to the 
Education Department. Many of the options, except online administration, 
would bring remote students back into buildings, although the guidance 
says students should not come in solely for standardized testing if health 
and safety conditions do not allow for that. James Cantonwine, director of 
research and assessment for Washington's Peninsula School District, 
said that means jumping logistical hurdles, including scheduling and 
space constraints, to allow for safe conditions. In addition, Marion said 
schools may need testing, contact tracing and additional resources to 
successfully carry out their efforts. https://www.k12dive.com/news/how-
will-districts-prepare-for-2020-21-summative-testing/595565/  
o States must still do all they can to measure student learning levels so 
schools can make progress in advancing educational equity, identifying 
student needs and targeting resources for interventions, the department 
said in a letter addressed to chief state school officers. In what it calls 
“significant flexibility,” the department is encouraging states to consider 
waivers that would not require that calculation of progress toward long-
term goals and measurements of interim progress or indicators. A waiver 
also would allow states to forgo the requirement to implement and report 
results of its accountability system. States would still need to maintain all 
state and local report card requirements and disaggregate data by 
student groups. However, reporting related to accountability, like school 



















• Governor Andrew M. Cuomo announced 12 community-based pop-up vaccination sites 
coming online this week at community centers, public housing complexes and cultural 
centers. These sites are expected to vaccinate more than 3,700 people throughout the 
week, with more sites coming online every week. Since January 15, more than 100 
community-based pop-up sites administered over 46,000 first doses of the COVID-19 
vaccine dose. As has been the case with previous pop-up sites, these sites will be re-
established in three weeks to administer second doses. Moving forward as the federal 
vaccine supply increases, New York will continue to establish these sites at all 33 
NYCHA Senior Housing Developments, which house more than 7,600 seniors. Pop-up 
locations will also continue to be established at other public housing complexes 
statewide, as well as at more than 300 churches and cultural centers which have 
volunteered to house these sites through Governor Cuomo's Vaccine Equity Task Force. 
https://www.governor.ny.gov/news/governor-cuomo-announces-12-community-based-
pop-vaccination-sites-coming-online-week-vaccinate  
• Governor Cuomo announced the State will partner with local health departments to 
include vaccination sites for the 65+ population across New York State. These sites will 
be in partnership with local health departments and, where needed, will provide 
assistance to New Yorkers with transportation to and from the vaccination facilities and 
special support for paperwork regarding their vaccination. As New York State’s vaccine 
allocations increase, these 65+ facilities and appointments will be enabled from 
additional supply from the federal government. Counties across New York State will be 
getting an increased supply of Moderna vaccine for this purpose starting next week. 
https://www.governor.ny.gov/news/governor-cuomo-announces-state-expand-
vaccination-network-include-sites-designed-serve-65-plus  
• Governor Cuomo today announced that the New York State Clinical Advisory Task 
Force unanimously recommended use of Janssen Pharmaceuticals/Johnson & 
Johnson's COVID-19 vaccine in New York State, following the FDA's advisory 
committee's recommendation for emergency use authorization. New York expects to 
receive approximately 164,800 doses of the Johnson & Johnson vaccine this week, 
pending final FDA authorization. The added doses will supplement New York State's 
expected Week 12 supply of 422,780 first doses and 290,500 second doses from Pfizer 
and Moderna, for a total of approximately 878,080 doses. This will be New York State's 
highest-ever weekly vaccine allocation. https://www.governor.ny.gov/news/governor-
cuomo-announces-state-vaccine-task-force-unanimously-recommends-jj-vaccine-one-
year    
 
New York State Department of Health (DOH) 
 
For a list of positive cases by county in New York State 
https://covid19tracker.health.ny.gov/views/NYS-COVID19-Tracker/NYSDOHCOVID-19Tracker-
Map?%3Aembed=yes&%3Atoolbar=no&%3Atabs=n  
NYS DOH has created a dynamic COVID-19 Tracker which provides COVID-19 information 
regarding testing, cases, percentages, and fatalities across New York State. It also breaks down 
cases by county.  
https://covid19tracker.health.ny.gov/views/NYS-COVID19-Tracker/NYSDOHCOVID-19Tracker-
Map?%3Aembed=yes&%3Atoolbar=no&%3Atabs=n  







• Governor Phil Murphy and Secretary of Higher Education Dr. Brian Bridges announced 
that $29.5 million in federal funding will be available to New Jersey’s institutions of 
higher education amid the ongoing COVID-19 pandemic to support the goals of 
the State Plan for Higher Education through a competitive challenge grant and address 
student food insecurities across college campuses. About $28.5 million in funding from 
the U.S. Department of Education through the Governor's Emergency Education Relief 
(GEER II) Fund will be awarded to New Jersey’s public and public-mission private 
institutions that receive state operating aid to implement vetted best practices that 
increase college completion, address barriers to student success, and develop 
sustainable systemic reforms. Another $1 million will be awarded to public institutions to 
combat food insecurity among students. 
https://nj.gov/governor/news/news/562021/approved/20210224b.shtml  
• On March 1, Governor Murphy announced the expansion of eligibility for more frontline 
essential workers and high-risk groups in New Jersey’s COVID-19 vaccination program. 
Eligible groups include educators and staff in pre-k through 12th grade 
settings, childcare workers, and transportation workers, among others. For a full list of 





• Governor Ned Lamont announced that his administration has filed an objection to 
motions under consideration at the Public Utilities Regulatory Authority (PURA) to 
approve plans submitted by Eversource Energy and the United Illuminating Company to 
begin allowing for the disconnection of customers for non-payment for the time since 
PURA first implemented a shut-off moratorium in response to the COVID-19 pandemic. 
The Lamont administration’s objections, which was made through the leadership of the 
Department of Energy and Environmental Protection (DEEP), noted that resuming 
disconnections at this time would have a devastating impact on many customers who 









Local Updates  
 
New York Blood Center (NYBC) 
 
Fox 5 Good Day New York’s recent segment highlighted the lifesaving power of convalescent 
plasma donation for critical COVID-19 patients. Brian Strauss was hospitalized with coronavirus and 
received lifesaving convalescent plasma. He was grateful for the opportunity to meet and thank his 




For the latest updated NYBC information about COVID-19: 
https://nybc.org/covid-19/  
 
New York City (NYC) Department of Health and Mental Hygiene (DOHMH)  
 
For NYC DOHMH updated COVID-19 data page 
https://www1.nyc.gov/site/doh/covid/covid-19-data.page  
 
For the latest COVID-19 information from NYC DOHMH 
https://www1.nyc.gov/site/doh/covid/covid-19-main.page 
 
Westchester County Department of Health 
 




For the latest COVID-19 information in Westchester including how to avoid the latest vaccine scams 
offering earlier access to vaccines. 
https://health.westchestergov.com/2019-novel-coronavirus  
 
Putnam County Department of Health 




For the latest COVID-19 information 
https://www.putnamcountyny.com/health/coronavirus/ 
 
Dutchess County Department of Health 
 
Breakdown of positive cases in Dutchess County as of March 1, 2021 
https://www.dutchessny.gov/Departments/DBCH/covid-19-dashboard.htm  
 
For the latest COVID-19 information: 
https://www.dutchessny.gov/Departments/DBCH/2019-Novel-Coronavirus.htm 
 
Orange County Department of Health 
 




For the latest COVID-19 information  
https://www.orangecountygov.com/1906/2019-Novel-Coronavirus-Information 
 
Rockland County Department of Health 
 
Review Rockland County’s dashboard with the latest COVID-19 information regarding cases as of 
March 1, 2021 
https://www.arcgis.com/apps/opsdashboard/index.html#/d074e0336e81449393a76d1768ceb096  
 





GNYHA provides updated New York Stat guidance information regarding Johnson & Johnson 
COVID-19 Vaccine Emergency Use Authorization 
https://www.gnyha.org/news/johnson-updated-new-york-state-guidance/  
 
For the latest COVID-19 information for healthcare facilities from the Greater New York Hospital 





Center for Disaster Medicine Media 
  
New York Medical College Leadership News: 
New York State's COVID Positivity Rate Drops Again With Johnson & Johnson Vaccine 
Approval On Horizon 




Robert Amler, M.D., M.B.A., dean of the School of Health Sciences and Practice and vice 
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Every effort is made to provide accurate and complete information in this newsletter. However, New 
York Medical College cannot guarantee that there will be no errors. NYMC makes no claims, promises or 
guarantees about the accuracy, completeness, or adequacy of the contents of the newsletters or the 
articles linked herein and further expressly disclaims liability for errors and omissions in the contents of 
this newsletter.  
 
This newsletter is for informational purposes only; it does not constitute medical advice. Always seek the 







New York Medical College 
Center for Disaster Medicine 
7 Dana Road Suite 511 
Valhalla, New York 10595 
914-594-1750 
https://www.nymc.edu/center-for-disaster-medicine/ 
 
 
 
 
 
 
